Skip to main content

News

ALN
October 01, 2020
In a new systematic review and meta-analysis, researchers assessed the risk of major cardiovascular events among adults with systemic lupus erythematosus compared with the general population or healthy controls.
The Dermatologist
October 01, 2020
Findings from a recent study assessed the risk of tuberculosis, latent tuberculosis, and tuberculosis reactivation among patients treated with secukinumab.
ALN
September 30, 2020
The new treatment option is the first fully human anti-TNF-α biologic agent administered via intravenous infusion approved for pediatric use in both active pJIA and active PsA.
ALN
September 29, 2020
While low-dose glucocorticoids are commonly used in the management of rheumatoid arthritis, the safety of the medications’ long-term use is unclear. Researchers evaluated the association between long-term low-dose glucocorticoid use and risk of hospitalized infection among patients with RA receiving stable DMARD therapy.
Rheumatology Consultant
September 25, 2020
In this podcast, Ana-Maria Orbai, MD, MHS, talks about the interchangeability between the HAQ-DI and PROMIS-PF in the measurement of minimal disease activity among patients with psoriatic arthritis and how it may influence your practice.
ALN
September 24, 2020
Past studies have determined the associations between plasma homocysteine levels and autoimmune diseases such as SLE and systemic sclerosis. Researchers now assessed the relationship between plasma homocysteine levels and dermatomyositis.
The Dermatologist
September 23, 2020
A recent study found rituximab infusions were associated with changes in heart rate and other cardiac adverse effects among patients with pemphigus.
Rheumatology Consultant
September 23, 2020
The American College of Rheumatology’s guideline for the treatment of rheumatoid arthritis includes recommendations on when to implement a treat-to-target strategy. Test your knowledge of these recommendations in our latest pop quiz!
ALN
September 23, 2020
The researchers assessed the association between drug use and subsequent diagnosis of cutaneous lupus erythematosus or systemic lupus erythematosus. Here is what they found about fexofenadine hydrochloride, levothyroxine sodium, and more.
ALN
September 22, 2020
The researchers assessed the incidence of psoriasis/psoriasiform rash, eczema, and skin infections among patients taking anti-TNF medications for the treatment of inflammatory bowel disease.
Back to Top